Related Experiment Video
Updated: Sep 28, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
NUT Carcinoma: Clinicopathologic Features, Molecular Genetics and Epigenetics.
Vanessa Moreno1, Karan Saluja1, Sergio Pina-Oviedo2
1Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.
Nuclear protein in testis (NUT) carcinoma is a rare, aggressive cancer defined by NUTM1 gene rearrangements, often forming BRD4-NUTM1 fusion oncogenes. Understanding these genetic alterations is key for developing targeted therapies for this challenging disease.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Nuclear protein in testis (NUT) carcinoma is a rare, aggressive malignancy primarily affecting adolescents and young adults.
- This cancer typically originates in midline thoracic, head, and neck structures, showing varied squamous differentiation.
- NUT carcinoma diagnosis hinges on identifying NUTM1 rearrangements, frequently involving BRD4.
Purpose of the Study:
- To review current clinicopathologic features of NUT carcinoma.
- To elucidate the role of NUTM1 gene rearrangements in cancer development.
- To explore how understanding molecular mechanisms can lead to novel targeted therapies.
Main Methods:
- Immunohistochemistry to detect nuclear NUT protein expression.
- Fluorescence in situ hybridization (FISH) for NUTM1 rearrangement detection.
- Reverse transcriptase PCR (RT-PCR) to identify fusion genes.
Main Results:
- NUTM1 rearrangements are the defining feature of NUT carcinoma.
- BRD4-NUTM1 fusion oncogene occurs in 70-80% of cases.
- Variant fusions like BRD3-NUTM1 and NSD3-NUTM1 are also observed.
Conclusions:
- NUT carcinoma is often underrecognized due to rarity and nonspecific features.
- NUTM1 gene rearrangements are crucial oncogenic drivers.
- Further research into molecular mechanisms may pave the way for targeted treatment strategies.
More Related Videos
07:00Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
Published on: February 28, 2019
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:38Mitogens and the Cell Cycle